SCHEMBL717243

SCHEMBL717243

OC(c1cc2ccccc2o1)C1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.48
CYP2D6 P10635 1/20 0.48
HIF1A Q16665 1/20 0.48
NPC1 O15118 4/20 0.47
MAOB P27338 2/20 0.47
KDM4E B2RXH2 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
MKNK1 Q9BUB5 1/20 0.40
POLB P06746 2/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717947 0.81 RAB9A (0.44) RAB9ACYP2D6HIF1ANPC1MAOB
SCHEMBL717242 0.77 KDM4E (0.50) RAB9ANPC1KDM4ECYP1A2MEN1
SCHEMBL720494 0.73 ADORA2A (0.53) RAB9ANPC1KDM4ECYP1A2CYP2C19
SCHEMBL719470 0.70 RCE1 (0.53) RAB9ANPC1MAOBKDM4ECYP1A2
SCHEMBL26326658 0.70 SLC6A2 (0.58) CYP2D6HIF1ACYP1A2MEN1KMT2A
SCHEMBL9811903 0.70 CYP2D6 (0.49) RAB9ACYP2D6HIF1ANPC1MAOB
SCHEMBL28591305 0.70 CYP2D6 (0.57) RAB9ACYP2D6HIF1ANPC1MAOB
SCHEMBL4047365 0.70 CYP2D6 (0.57) RAB9ACYP2D6HIF1ANPC1MAOB
SCHEMBL24173635 0.69 CYP2D6 (0.60) RAB9ACYP2D6HIF1ANPC1MAOB
SCHEMBL6622018 0.69 CYP2D6 (0.56) RAB9ACYP2D6HIF1ANPC1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RAB9A 2454/4885CYP2D6 639/4885HIF1A 1023/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RAB9A 2454/4885CYP2D6 639/4885HIF1A 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.